CSPC PHARMA 9M Net Profit RMB7.076B Up 101.5% YoY

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CSPC PHARMA (01093.HK) -0.225 (-2.852%) Short selling $203.82M; Ratio 36.092% announced its results for the first three quarters ended September 2026. Revenue amounted to RMB25.26 billion, up 27% YoY. Net profit rose 101.5% YoY to RMB7.076 billion, with EPS at RMB0.6214. Excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation expenses, underlying profit for the first three quarters amounted to RMB7.22 billion, up 134.5% YoY.


During the period, R&D expenses amounted to RMB4.643 billion, representing an increase of 10.9% compared with the same period last year, accounting for approximately 30.2% of finished drug business revenue.

Since the beginning of the year, the group's registration and approval progress in China included approval for the launch of seven new products; acceptance of marketing applications for 10 products; five breakthrough therapy designations granted; and 32 clinical trial approvals obtained. In overseas markets, the group also obtained 12 clinical trial approvals and one fast-track designation, while securing marketing approval in the European Union for one self-developed drug.(sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)

AASTOCKS Financial News

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.